Clinical Trial Update: WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating WAST Cell in combination with docetaxel for PD-1 inhibitor-resistant advanced non-small cell lung cancer; currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• WAST Cell

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Status: RECRUITING